NHS Long Term Plan 2020 - Partner Profile - AliveCor
Updated: Nov 27, 2019
Who are AliveCor?
AliveCor, Inc. is pioneering the creation of FDA-cleared machine learning techniques to enable proactive heart care and is recognized around the world for transforming cardiac care. The FDA-cleared KardiaMobile is the most clinically validated mobile ECG solution on the market. It is recommended by leading cardiologists and used by people worldwide for accurate ECG recordings. KardiaMobile, when paired with the Kardia app provide instant analysis for detecting atrial fibrillation (AF) and normal sinus rhythm in an ECG. Kardia is the first A.I. enabled platform to help clinicians manage patients for the early detection of atrial fibrillation, the most common cardiac arrhythmia and one that leads to a five times greater risk of stroke. AliveCor is recognized by FastCompany as 2018's No. 1 most innovative company in artificial intelligence. AliveCor is a privately held venture backed company headquartered in Mountain View, CA. For more information, visit alivecor.com.
How has AliveCor improved outcomes for the NHS and patients?
· Reduced rate of unnecessary cardiologist referrals – saving both resource and budget within the NHS
· Streamlined pathways - enhancing patient experience
· Improved patient outcomes – faster route to diagnosis of atrial fibrillation
· Quicker diagnosis could result in potential avoidance of stroke
· Supporting increase of atrial fibrillation detection, reducing detection gaps
What has been your greatest achievement to date? And were there any measurable outcomes that accompanied this achievement?
· The first FDA-approved personal, mobile ECG device
· The most used personal ECG device in the world
· The most clinically-validated personal ECG device in the world
How many organisations / clients currently utilise the service / solution across the UK?
· Representation in both Primary and Secondary Care settings, and listed on NHS Supply Chain
· Used within 20%+ of CCGs in the UK
· 5,732 devices distributed by the 15 AHSNs within England, during 2018
· Available as a consumer device to the general public
What do you feel are the key points delegates need to digest when considering a partnership with AliveCor?
· Most clinically-validated personal ECG in the world
· FDA cleared in the US, and CE-marked in Europe
· 84 clinical peer-reviewed papers
If you would like to learn more about AliveCor please visit https://shop.gb.alivecor.com/